Biotech Laboratories (pty) Ltd Pharmaceutical Import Profile — South Africa (DGFT 2022–2026)

Name: Biotech Laboratories (pty) Ltd Pharmaceutical Import Records from India — 5 Products, $4.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biotech Laboratories (pty) Ltd — Pharmaceutical Importer Profile (2026) | 5 Products, $4.8M Trade | TransData Nexus

Biotech Laboratories (pty) Ltd

Pharmaceutical Importer · South Africa · Cardiovascular Focus · $4.8M Total Trade · DGFT Verified

Biotech Laboratories (pty) Ltd is a pharmaceutical importer based in South Africa with a total trade value of $4.8M across 5 products in 4 therapeutic categories. Based on 277 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Biotech Laboratories (pty) Ltd sources from 2 verified Indian suppliers, with J B Chemicals And Pharmaceuticals Limited accounting for 76.3% of imports.

Biotech Laboratories (pty) Ltd — Import Portfolio & Supplier Network

Biotech Laboratories (pty) Ltd import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Biotech Laboratories (pty) Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
J B Chemicals And Pharmaceuticals Limited	$1.4M	93	76.3%
J B Chemicals Pharmaceuticals Limited	$419.2K	36	23.7%

Biotech Laboratories (pty) Ltd sources from across .

What Formulations Does Biotech Laboratories (pty) Ltd Import?

Formulation	Value	Ships
Enalapril maleate tablets USP 20MG eachtablet contains enalapril maleate USP 20MG enalapril 20MG biotech 3x10s sa	$194.1K	4
Bio baclofen 10MG 3x10tabs sa	$146.1K	3
Cimetidine tablets USP 400MG bio cimetidine tabs 400MG 4x14 sa exp total qty consumed adv lic no	$100.0K	2
Klarizon 500 clarithromycin 500MG TAB	$82.2K	4
Fungistop topical cream 1% 20GM sa packsize-20GM	$77.7K	12
Metformin 500 56s sa biotech	$75.1K	2
Silbecor 1% cream 50GM sa exp	$54.0K	2
Nifedipine extended release tablets 60mgeach tablet contains sentry polyox wsrcoagulant nf 113 60 MG eastman	$50.0K	1
Paracetamol biotech iv1x100ml	$50.0K	1
Tranexamic acid injection BP 500 MG 5ML Each 5ML contains tranexamic acid bp500 MG tranmenxio iv 500MG 5ML	$50.0K	1
Metronidazole tablets 400MG bio metronidazole TAB 400 MG 500s sa	$50.0K	1
Doxycycline biotech 100MG. Each tablet contains doxycycline hyclate 100.00 MG doxycycline 100MG TAB 100's sa	$47.5K	2
Azithromycin 500 biotech 1x3t sa-	$46.0K	1
Clarithromycin tablets USP 500 MG eachtablet contains clarithromycin USP 500MG klarizon	$45.9K	2
Klarizon 500 clarithromycin 500MG TAB klarizon 500 total qty consumed gr wt 51	$41.3K	2

Biotech Laboratories (pty) Ltd imports 85 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Azithromycin	Antibiotics	$1.6M	33	0.9%	15
2	Metronidazole	Advanced Antibiotics	$1.3M	109	0.7%	15
3	Enalapril	Cardiovascular	$1.3M	108	0.5%	5
4	Nifedipine	Cardiovascular	$550.1K	18	1.8%	13
5	Glibenclamide	Advanced Diabetes Medications	$81.1K	9	0.2%	7

Biotech Laboratories (pty) Ltd imports 5 pharmaceutical products across 4 categories into South Africa totaling $4.8M.

Biotech Laboratories (pty) Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Biotech Laboratories (Pty) Ltd, established in 1991, is a South African pharmaceutical company specializing in the marketing, sales, and distribution of generic and branded pharmaceuticals. The company serves both the private and public sectors within South Africa and extends its reach to export markets within the Southern African Development Community (SADC) region. Its product portfolio spans various therapeutic categories, including anti-infectives, anti-inflammatories, and treatments for cardiovascular, central nervous, and respiratory systems, as well as the urinary and gastrointestinal tracts.

In 2015, Biotech Laboratories became a subsidiary of J.B. Chemicals & Pharmaceuticals Ltd, a leading Indian pharmaceutical company, by acquiring a 51% stake. This strategic acquisition aimed to strengthen Biotech's position in the South African market and enhance its distribution capabilities. The company's headquarters are located at Block K West, 400 16th Road, Central Park, Randjespark, Midrand, 1685, South Africa.

2Distribution Network

Biotech Laboratories operates a comprehensive distribution network within South Africa, ensuring the efficient delivery of pharmaceutical products to various healthcare providers. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic acquisition by J.B. Chemicals & Pharmaceuticals Ltd suggests an integrated supply chain that leverages both local and international resources. This integration likely enhances Biotech's ability to manage inventory, streamline distribution processes, and maintain a consistent supply of products across the region.

3Industry Role

Biotech Laboratories (Pty) Ltd plays a pivotal role in South Africa's pharmaceutical supply chain as a primary wholesaler and distributor. By importing and distributing a diverse range of pharmaceutical products, the company ensures the availability of essential medications to meet the healthcare needs of the South African population. Its strategic partnership with J.B. Chemicals & Pharmaceuticals Ltd further solidifies its position in the market, enabling access to a broader portfolio of products and enhancing its distribution capabilities.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Biotech Laboratories (pty) Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Biotech Laboratories demonstrates a high degree of supplier concentration, with 93% of its imports from India sourced from J.B. Chemicals & Pharmaceuticals Ltd. This significant reliance on a single supplier indicates a strategic choice to maintain consistent product quality and supply chain efficiency. However, such concentration also exposes the company to potential risks associated with supply chain disruptions, regulatory changes, or operational challenges faced by the supplier. The stability of this relationship is crucial for Biotech's operations, and any adverse developments could impact its ability to meet market demand.

2Supply Chain Resilience

The resilience of Biotech Laboratories' supply chain is closely tied to the stability and reliability of J.B. Chemicals & Pharmaceuticals Ltd. While the company's focus on a single supplier may streamline operations, it also means that any disruptions in the supplier's production or distribution could significantly affect Biotech's ability to deliver products. The lack of publicly available information regarding backup suppliers or alternative sourcing strategies suggests a potential vulnerability in the supply chain. Additionally, the diversity of formulations imported indicates a broad product range, but the heavy reliance on one supplier for these products may limit flexibility in responding to market changes or demands.

Importing Pharmaceuticals into South Africa — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for South Africa

1Regulatory Authority & Framework

In South Africa, the South African Health Products Regulatory Authority (SAHPRA) is responsible for regulating the registration, importation, and distribution of pharmaceutical products. SAHPRA ensures that all medicines meet the required safety, efficacy, and quality standards before they are made available to the public. The Medicines and Related Substances Act, 1965 (Act No. 101 of 1965) serves as the primary legislation governing the control of medicines and related substances in South Africa. This Act outlines the procedures for the registration of medicines, the establishment of standards, and the control of the importation and distribution of pharmaceutical products.

2Import Licensing & GMP

Pharmaceutical manufacturers and wholesalers in South Africa are required to obtain licenses from SAHPRA to import and distribute medicines. These licenses are contingent upon compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) guidelines issued by SAHPRA. Additionally, entities must be registered with the South African Pharmacy Council as a manufacturing or wholesale pharmacy and appoint a responsible pharmacist to oversee operations. For Indian exporters, recognition of GMP certificates from reputable authorities such as the European Union (EU), World Health Organization (WHO), or Pharmaceutical Inspection Co-operation Scheme (PIC/S) is essential for the acceptance of their products in the South African market.

Biotech Laboratories (pty) Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Biotech Laboratories' focus on importing products in the cardiovascular, antibiotics, and advanced antibiotics categories aligns with the prevalent health challenges in South Africa, where cardiovascular diseases and infectious diseases are leading causes of morbidity and mortality. The market demand for effective treatments in these therapeutic areas drives the company's import strategy, ensuring the availability of essential medications to address these health concerns. By concentrating on these categories, Biotech Laboratories aims to meet critical healthcare needs and strengthen its position in the South African pharmaceutical market.

2Sourcing Profile

Biotech Laboratories primarily sources generic pharmaceutical products from India, leveraging the country's established manufacturing capabilities and cost advantages. The company's preference for finished pharmaceutical formulations over raw Active Pharmaceutical Ingredients (APIs) indicates a focus on ready-to-market products that can be swiftly distributed. India's compliance with international GMP standards and its competitive pricing make it a strategic partner for Biotech Laboratories in fulfilling the South African market's demands.

3Market Positioning

Seller's Guide — How to Become a Supplier to Biotech Laboratories (pty) Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Biotech Laboratories' supply chain, provided they can meet the stringent quality standards and regulatory requirements set by SAHPRA. Gaps in Biotech's current sourcing may exist in specific therapeutic areas or formulations not currently covered. New suppliers can explore these niches by offering innovative products or addressing unmet needs in the South African market. Building a strong relationship with Biotech Laboratories and demonstrating the ability to consistently supply high-quality products will be crucial for success.

2Requirements & Qualifications

Indian exporters aiming to supply Biotech Laboratories and the South African market must possess valid GMP certificates recognized by SAHPRA, such as those from the EU, WHO, or PIC/S. Additionally, they must comply with SAHPRA's import licensing requirements, including the appointment of a responsible pharmacist and adherence to GDP guidelines. Ensuring that products meet South African labeling and serialization standards is also essential for market acceptance.

3How to Approach

Frequently Asked Questions — Biotech Laboratories (pty) Ltd

What products does Biotech Laboratories (pty) Ltd import from India?

Biotech Laboratories (pty) Ltd imports 5 pharmaceutical products across 4 categories. Top imports: Azithromycin ($1.6M), Metronidazole ($1.3M), Enalapril ($1.3M), Nifedipine ($550.1K), Glibenclamide ($81.1K).

Who supplies pharmaceuticals to Biotech Laboratories (pty) Ltd from India?

Biotech Laboratories (pty) Ltd sources from 2 verified Indian suppliers. The primary supplier is J B Chemicals And Pharmaceuticals Limited (76.3% of imports, $1.4M).

What is Biotech Laboratories (pty) Ltd's total pharmaceutical import value?

Biotech Laboratories (pty) Ltd's total pharmaceutical import value from India is $4.8M, based on 277 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Biotech Laboratories (pty) Ltd focus on?

Biotech Laboratories (pty) Ltd imports across 4 categories. The largest: Cardiovascular (37.4%), Antibiotics (33.5%), Advanced Antibiotics (27.4%).

Get Full Biotech Laboratories (pty) Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.